doxorubicin hydrochloride / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   643 Trials   643 Trials   26774 News 


«12...89101112131415161718...521522»
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Conjugate of Natural Bacteriochlorin with Doxorubicin for Combined Photodynamic and Chemotherapy. (Pubmed Central) -  Jul 13, 2024   
    In vitro and in vivo studies showed a more pronounced activity of the conjugate against MCF-7 and 4T1 cells and its higher tumorotropicity in animal tumor-bearing animals compared to free anthracycline antibiotic. The suggested conjugate implements the advantages of photodynamic therapy and chemotherapy and has great potential in cancer treatment.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Review, Journal:  Antibody-Drug Conjugates-Evolution and Perspectives. (Pubmed Central) -  Jul 13, 2024   
    Major aspects such as development strategies are first discussed, advantages and disadvantages, safety and efficacy, offering a retrospective insight on the subject. The second part of the review is prospective, focusing on various plans to overcome the previously identified difficulties.
  • ||||||||||  cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
    Journal:  Combined Application of Cold Physical Plasma and Chemotherapeutics against Chondrosarcoma Cells. (Pubmed Central) -  Jul 13, 2024   
    This combined approach significantly reduced the cell proliferation and viability while increasing the apoptosis signals compared to cytostatic therapy alone. The combination of CPP and chemotherapeutic drugs shows promise in targeting chemoresistant CS cells, potentially improving the prognosis for patients in clinical settings.
  • ||||||||||  Journal:  Rare case of myelodysplastic syndrome with excess blasts (Pubmed Central) -  Jul 12, 2024   
    Due to the rarity of BS, there is no prospective trial in patients with cancer and no evidence base upon which to design treatment programs. For these reasons, it is strongly recommended that patients receive multidisciplinary care, with precise assessment and discussion of the indication and an adequate dose of DNA-damaging agents such as chemotherapy and ionizing radiation.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Review, Journal:  Natural Products for Preventing and Managing Anthracycline-Induced Cardiotoxicity: A Comprehensive Review. (Pubmed Central) -  Jul 12, 2024   
    This review presents an overview of current knowledge on doxorubicin DOX-induced cardiotoxicity, with a focus on the potential benefits of natural compounds and herbal preparations in preventing this adverse effect. As literature search engines, the browsers in the Scopus, PubMed, Web of Science databases and the ClinicalTrials.gov register were used.
  • ||||||||||  cytarabine / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Journal:  Targeting HMGCS1 restores chemotherapy sensitivity in acute myeloid leukemia. (Pubmed Central) -  Jul 12, 2024   
    Furthermore, combination of hymeglusin and the common chemotherapeutic drug cytarabine and adriamycin (ADR) had synergistic toxic effects on AML cells. Our study demonstrates the important role of HMGCS1 in AML, and targeting this protein is promising for the treatment of RR AML.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg., sorafenib / Generic mfg.
    Journal:  A Homologous Membrane-Camouflaged Self-Assembled Nanodrug for Synergistic Antitumor Therapy. (Pubmed Central) -  Jul 11, 2024   
    Therefore, we developed a simple and high-efficiency nanodrug composed of self-assembling by Fe2+ sources, H2O2 inducer and ROS resistance inhibitors. This nanodrug can effectively deliver the Fe2+ sources into tumor tissue, enhance intracellular concentration of H2O2, and reduce ROS resistance, achieving a high-efficiency, precise and safe ferroptosis therapy.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Lignin-Based Nanoparticles for Combination of Tumor Oxidative Stress Amplification and Reactive Oxygen Species Responsive Drug Release. (Pubmed Central) -  Jul 11, 2024   
    Doxorubicin (DOX) was attached to the ROS-cleavable bond in the LG-M(TK)-PEG for the preparation of the ROS-activatable DOX prodrug (LG-M(TK-DOX)-PEG)...This selective effect facilitated the specific activation of the DOX prodrug in the tumor microenvironment, resulting in the superior tumor inhibitory effects and enhanced biosafety relative to free DOX. This work demonstrates the potential of the LG-M(TK-DOX)-PEG NPs as an efficient drug delivery system for cancer treatment.
  • ||||||||||  Pinorubin (pirarubicin) / Sanofi
    Review, Journal:  An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity. (Pubmed Central) -  Jul 11, 2024   
    Mechanisms and protective strategies associated with anthracycline cardiotoxicity in animal experiments are examined, and the definition of drug damage in humans and animal models is discussed. Understanding these molecular mechanisms is of paramount importance in mitigating anthracycline-induced cardiac toxicity and guiding the development of safer approaches in cancer treatment.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg., gemcitabine / Generic mfg., sorafenib / Generic mfg.
    Journal, Tumor mutational burden, Gene Signature, PD(L)-1 Biomarker, IO biomarker:  Construction and validation of a prognostic and therapeutic cuproptosis- and immune-related gene signature in hepatocellular carcinoma. (Pubmed Central) -  Jul 11, 2024   
    Low-risk patients responded well to immunotherapy treatment, whereas high-risk patients were more sensitive to sorafenib, doxorubicin, gemcitabine and AKT (also known as protein kinase B) inhibitors. The established risk signature based on CIRGs can not only well predict the prognosis of HCC patients but is also promising in evaluating TMB and treatment response to immunotherapy, targeted therapy and chemotherapy, which has the potential to assist in the clinical management of HCC.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Protosappanin A Protects DOX-Induced Myocardial Injury and Cardiac Dysfunction by Targeting ACSL4/FTH1 Axis-Dependent Ferroptosis. (Pubmed Central) -  Jul 10, 2024   
    Doxorubicin (DOX) is an effective anticancer agent, but its clinical utility is constrained by dose-dependent cardiotoxicity, partly due to cardiomyocyte ferroptosis...Given the critical role of ferroptosis in the pathogenesis of ischemia-reperfusion (IR) injury, this further investigation posits that PrA can confer a protective effect against IR-induced cardiac damage by inhibiting ferroptosis. Overall, a novel pharmacological inhibitor is unveiled that targets ferroptosis and uncover a dual-regulated mechanism for cardiomyocyte ferroptosis in DIC, highlighting additional therapeutic options for chemodrug-induced cardiotoxicity and ferroptosis-triggered disorders.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Preclinical, Journal, IO biomarker:  Synthesis, anticancer evaluation of novel hybrid pyrazole-based chalcones, molecular docking, DNA fragmentation, and gene expression: in vitro studies. (Pubmed Central) -  Jul 10, 2024   
    When compared to the reference medicine doxorubicin (IC50 = 52.1 ?M), compound 9e showed the most promise derivative (IC50 = 27.6 ?M) against PACA2 cells, while compound 7d demonstrated anticancer efficacy (IC50 = 42.6 ?M against MCF7 cells compared to the reference drug doxorubicin (IC50 = 48 ?M)...Moreover, the molecular docking study of compounds 7d and 9e was assessed. The binding affinities of compound 9e toward P53 mutant Y220C was -22 kcal per mole, while those of compound 7d towards Bcl2 and CDK4 were -27.81 and -26.9 kcal per mole, respectively, compared to the standard values (-15.82, -33.96 and -29.9 kcal per mole).
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Preclinical, Journal:  A novel nanodrug for the sensitization of photothermal chemotherapy for breast cancer in vitro. (Pubmed Central) -  Jul 8, 2024   
    In this work, polylactic acid-based drug nanoparticles (PLA@DOX/GA/ICG) were synthesized with good photothermal conversion ability by encapsulating the water-soluble anticancer drug doxorubicin (DOX), photothermal conversion agent indocyanine green (ICG) and liposoluble drug gambogic acid (GA) using a double emulsion method...Gambogic acid entrapped in PLA@DOX/GA/ICG nanoparticles could act as an HSP90 protein inhibitor to achieve bidirectional sensitization to chemotherapy and photothermal therapy under 808 nm laser irradiation for the first time, effectively ablating breast cancer cells in vitro. This nanodrug was expected to be used for the efficient treatment of tumors.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Remotely Controlled Surface Charge Modulation of Magnetoelectric Nanogenerators for Swift and Efficient Drug Delivery. (Pubmed Central) -  Jul 8, 2024   
    We have developed a highly efficient technique of magnetically controlled swift loading and release of doxorubicin (DOX) drug using a magnetoelectric nanogenerator (MENG)...In vitro, experiments validate the cytocompatibility and magnetically assisted on-demand and swift DOX drug delivery by the MENG near MCF-7 breast cancer cells, which results in a significant enhancement of cancer cell killing efficiency. A state-of-the-art experiment was performed to visualize the nanoscale magnetoelectric effect of MENG using off-axis electron holography under Lorentz conditions.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Hyaluronic acid nanoparticles for targeted oral delivery of doxorubicin: Lymphatic transport and CD44 engagement. (Pubmed Central) -  Jul 6, 2024   
    In vivo imaging and pharmacodynamic studies indicated that HGD possessed tumor-targeting capabilities and exhibited a significant inhibitory effect on tumor growth, while maintaining an acceptable safety profile. Collectively, these findings position HGD-DOX nanoparticles as a promising strategy to boost the oral bioavailability of DOX, offering a potential avenue for improved cancer treatment.